Research method
Bisulfite Sequencing
Bisulfite sequencing treats DNA with bisulfite so unmethylated cytosines deaminate to uracil while 5-methylcytosine is protected, then sequences the converted DNA to call CpG methylation. The output is a percent-methylated map at assayed sites — a few targeted CpGs, a 27K array, or a genome-wide epiallele screen — not proof that those sites cause ageing or cancer. Array chemistries and conversion biases are part of the result.
Epigenetic studies use bisulfite methods when they need to know which cytosines are methylated across people, ages, or tissues. It answers 'how methylated is this locus, and does that track environment or genotype?' Its main limitation is that methylation association is not disease causation, transformed cell lines can distort patterns, and not every epigenetics paper in this list actually converted DNA with bisulfite.
Evidence
What the evidence shows
Drawn from 4 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Independent genome-wide screens for systemic interindividual methylation converged on VTRNA2-1: concordant multi-tissue differences, partly set by periconceptional environment (season of conception in Gambian infants), and stable for at least 10 years. Metastable epiallele regions were depleted for CGIs/SINEs and enriched for LINEs/ERVs. Epiallele status is not itself proof of disease causation in every tissue.
From 575 blood DNA-methylation profiles (ages 0–78), 102 age-related CpGs were selected (58 hypo, 44 hyper). A three-CpG bisulfite signature predicted age with mean absolute deviation 3.34 years (R²=0.98). CpG changes were not shown to cause ageing diseases.
Illumina 27K methylation in 77 Yoruba lymphoblastoid cell lines tracked genotypes and correlated with RNA-seq expression. LCLs are transformed lines, so primary-tissue methylation may differ.
FECR1, a FLI1 exonic circular RNA, was recovered by dCas9 chromatin immunoprecipitation at the FLI1 promoter in MDA-MB231 cells, activates FLI1 via TET1/DNMT1 regulation, and promotes invasive phenotypes, with FLI1 elevated in tumour versus adjacent tissue. That is CasIP and chromatin-modifier genetics, not a bisulfite methylome; human data are observational staining/expression, not a circRNA therapy trial.
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
Bisulfite designs here are not one map. VTRNA2-1 is a multi-tissue epiallele stable ≥10 years and sensitive to periconceptional season; the ageing paper compresses 102 AR-CpGs into a 3-site blood clock (MAD 3.34 years); Yoruba 27K arrays link methylation to genetics and expression in 77 LCLs. A clock CpG is not an environment-set metastable epiallele.
- VTRNA2-1: an environment-sensitive human epiallele
- Three CpGs track blood aging
- Genetics shapes methylation and expression
Study Role Design N Population Outcome VTRNA2-1: an environment-sensitive human epiallele Supports OtherMulti-tissue metastable-epiallele screens plus Gambian season-of-conception methylation analyses N=215 · Season-of-conception contrast: 110 dry-season vs 105 rainy-season conceptions; additional multi-tissue discovery screens Human multi-tissue DNA methylomes and Gambian infant cohorts Systemic interindividual methylation at VTRNA2-1 and periconceptional environment effects Three CpGs track blood aging Supports Computational / modellingCombined blood DNAm datasets to select age-related CpGs and train a 3-site age predictor N=575 · 575 DNAm profiles from four studies, ages 0–78 Human blood DNA methylation profiles across childhood to older adulthood Epigenetic age prediction from blood CpG methylation Genetics shapes methylation and expression Supports Cross-sectionalIllumina 27K promoter methylation in Yoruba HapMap LCLs linked to genotypes and RNA-seq N=77 · 77 LCLs; RNA-seq available for 69 HapMap Yoruba lymphoblastoid cell lines Genetic and expression correlates of inter-individual DNA methylation FECR1 is a false-positive or peripheral hit for bisulfite sequencing: promoter RNA pull-down and TET1/DNMT1 regulation of FLI1, not a converted-cytosine map. Citing it as a methylome paper confuses chromatin RNA occupancy with CpG calls.
Common misconceptions
A three-CpG signature with R²=0.98 means those sites cause ageing.
From 575 blood profiles (ages 0–78), 102 AR-CpGs (58 hypo, 44 hyper) were used to train predictors; the 3-site assay had MAD 3.34 years. Tracking age is not proof that CpG changes cause ageing diseases.
If methylation in 77 Yoruba LCLs matches genotype and RNA-seq, the same map holds in primary tissues.
LCLs are transformed lines, so methylation–expression links may differ from primary tissues even when genetics tracks methylation on a 27K array.
VTRNA2-1 methylation that is stable for ≥10 years must be purely genetic and independent of environment.
The epiallele is concordant across tissues and long-term stable, yet partly set by periconceptional environment (season of conception in Gambian infants). Stability after setting is not the same as genetic determinism.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Why can VTRNA2-1 be both environment-sensitive at conception and stable for at least 10 years without contradiction?
Periconceptional season can set the epiallele; once set, multi-tissue methylation remains concordant and stable for ≥10 years. Setting window and later stability are different timescales.
A blood clock uses three CpGs with MAD 3.34 years after seeing 102 AR-CpGs in 575 people. What is lost when you drop from 102 sites to three, and what is not claimed?
Most age-correlated CpGs (58 hypo, 44 hyper) are not in the 3-site assay; the three are a practical predictor (R²=0.98). The paper does not claim those CpGs cause ageing diseases.
Yoruba LCL methylation tracks genotype and RNA-seq. Why might a primary-tissue methylome disagree?
LCLs are transformed lines. Array methylation (27K) in 77 lines can capture genetic effects that still differ from untransformed tissues.
FECR1 activates FLI1 via TET1/DNMT1 after CasIP at the promoter. Why is that a weak bisulfite-sequencing example?
The method is dCas9 chromatin immunoprecipitation of RNAs at the FLI1 promoter plus modifier genetics, not cytosine conversion maps. Tumour-versus-adjacent FLI1 elevation is observational expression/staining.
The studies
4 studies in this library bear on Bisulfite Sequencing, ordered by citations.
- Genetics shapes methylation and expression
In HapMap LCLs, promoter methylation associates with genetic variants and transcript levels.
- Three CpGs track blood aging
Age-related blood DNA methylation at a few CpGs predicts chronological age with ~3.3-year MAD.
- FLI1 circRNA FECR1 drives metastasis
Exonic circular RNA FECR1 binds the FLI1 promoter and epigenetically activates FLI1 in breast cancer.
- VTRNA2-1: an environment-sensitive human epiallele
Independent genome-wide methylation screens converge on VTRNA2-1 as a systemic metastable epiallele shaped by periconceptional environment and stable for years.
Learn alongside